TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06138639: A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

Sponsor: Solid Biosciences Inc. · Phase: PHASE1/PHASE2 · Area: RARE_ORPHAN · Target Enrollment: 60 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$2,407,625

Rescue Site Savings

+$1,575,900

Unlock Full NCT06138639 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06138639 Rescue Dossier →